Skip to main content
SpringerLink
Log in

Bedeutung der Dauer einer begleitenden Hormontherapie zur definitiven Strahlentherapie

Significance of duration of concurrent hormone therapy and definitive radiotherapy

  • Journal Club
  • Published:
Die Urologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Zapatero A, Guerrero A, Maldonado X, Alvarez A, Gonzalez San Segundo C, Cabeza Rodriguez MA, Macias V, Olive PA, Casas F, Boladeras A et al (2015) High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. Lancet Oncol 16:320–327. https://doi.org/10.1016/S1470-2045(15)70045-8

    Article  CAS  Google Scholar 

  2. Zapatero A, Guerrero A, Maldonado X, Alvarez A, Gonzalez-San SC, Cabeza Rodriguez MA, Macias V, Olive PA, Casas F, Boladeras A et al (2016) Late radiation and cardiovascular adverse effects after androgen deprivation and high-dose radiation therapy in prostate cancer: results from the DART 01/05 randomized phase 3 trial. Int J Radiat Oncol Biol Phys 96:341–348. https://doi.org/10.1016/j.ijrobp.2016.06.2445

    Article  Google Scholar 

  3. Zapatero A, Guerrero A, Maldonado X, Alvarez A, San-Segundo CG, Rodriguez MAC, Sole JM, Olive AP, Casas F, Boladeras A et al (2022) High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial. Lancet Oncol 23:671–681. https://doi.org/10.1016/S1470-2045(22)00190-5

    Article  Google Scholar 

  4. Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, Gez E, Kil P, Akdas A, Soete G et al (2009) Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360:2516–2527. https://doi.org/10.1056/NEJMoa0810095

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Radioonkologie und Strahlentherapie, Campus Benjamin Franklin, Charité Universitätsmedizin Berlin, Hindenburgdamm 30, 12203, Berlin, Deutschland

    Dirk Böhmer

  2. Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Ulm, Ulm, Deutschland

    Thomas Wiegel

  3. Xcare Gruppe Radiologie, Nuklearmedizin und Strahlentherapie, Saarlouis, Deutschland

    Stefan Höcht

  4. Univ.-Klinik für Strahlentherapie-Radioonkologie, Innsbruck, Österreich

    Ute Ganswindt

Authors
  1. Dirk Böhmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Wiegel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stefan Höcht
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ute Ganswindt
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

AG Prostata der Deutschen Gesellschaft für Radioonkologie

Corresponding author

Correspondence to Dirk Böhmer.

Ethics declarations

Interessenkonflikt

D. Böhmer, T. Wiegel, S. Höcht und U. Ganswindt geben an, dass kein Interessenkonflikt besteht.

Additional information

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Böhmer, D., Wiegel, T., Höcht, S. et al. Bedeutung der Dauer einer begleitenden Hormontherapie zur definitiven Strahlentherapie. Urologie 61, 1387–1389 (2022). https://doi.org/10.1007/s00120-022-01960-y

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-022-01960-y

Search

Navigation